E
Eugene J. Mark
Researcher at Harvard University
Publications - 525
Citations - 28749
Eugene J. Mark is an academic researcher from Harvard University. The author has contributed to research in topics: Presentation (obstetrics) & Lung cancer. The author has an hindex of 60, co-authored 525 publications receiving 27348 citations. Previous affiliations of Eugene J. Mark include Cornell University & Armed Forces Institute of Pathology.
Papers
More filters
Journal ArticleDOI
Case records of the Massachusetts General Hospital.
Journal ArticleDOI
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Lecia V. Sequist,Belinda A. Waltman,Dora Dias-Santagata,Subba R. Digumarthy,Alexa B. Turke,Panos Fidias,Kristin Bergethon,Alice T. Shaw,Scott N. Gettinger,Arjola K. Cosper,Sara Akhavanfard,Rebecca S. Heist,Jennifer S. Temel,James G. Christensen,John C. Wain,Thomas J. Lynch,Kathy Vernovsky,Eugene J. Mark,Michael Lanuti,A. John Iafrate,Mari Mino-Kenudson,Jeffrey A. Engelman +21 more
TL;DR: Detailed genetic and histological analysis of 37 patients with drug-resistant non–small cell lung cancers carrying EGFR mutations provides new insights into the shifting sands of drug resistance evolution in lung cancers and suggests that serial biopsies may be essential in the quest to reverse or even prevent the development ofdrug resistance.
Journal ArticleDOI
Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses
Arindam Bhattacharjee,William G. Richards,Jane Staunton,Cheng Li,Stefano Monti,Priya Vasa,Christine Ladd,Javad Beheshti,Raphael Bueno,Michael A. Gillette,Massimo Loda,Griffin M. Weber,Eugene J. Mark,Eric S. Lander,Wing Hung Wong,Bruce E. Johnson,Todd R. Golub,Todd R. Golub,David J. Sugarbaker,Matthew Meyerson +19 more
TL;DR: A molecular taxonomy of lung carcinoma is generated and results suggest that integration of expression profile data with clinical parameters could aid in diagnosis of lung cancer patients.
Journal ArticleDOI
Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK
Alice T. Shaw,Beow Y. Yeap,Mari Mino-Kenudson,Subba R. Digumarthy,Daniel B. Costa,Rebecca S. Heist,Benjamin Solomon,Hannah Stubbs,Sonal Admane,Ultan McDermott,Jeffrey Settleman,Susumu Kobayashi,Eugene J. Mark,Scott J. Rodig,Lucian R. Chirieac,Eunice L. Kwak,Thomas J. Lynch,A. John Iafrate +17 more
TL;DR: EML4-ALK defines a molecular subset of NSCLC with distinct clinical characteristics and patients who harbor this mutation do not benefit from EGFR TKIs and should be directed to trials of ALK-targeted agents.
Journal ArticleDOI
ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers
Kristin Bergethon,Alice T. Shaw,Sai-Hong Ignatius Ou,Ryohei Katayama,Christine M. Lovly,Nerina T. McDonald,Pierre P. Massion,Christina Siwak-Tapp,Adriana Gonzalez,Rong Fang,Eugene J. Mark,Julie M. Batten,Haiquan Chen,Keith D. Wilner,Eunice L. Kwak,Jeffrey W. Clark,David P. Carbone,Hongbin Ji,Jeffrey A. Engelman,Mari Mino-Kenudson,William Pao,A. John Iafrate +21 more
TL;DR: ROS1 rearrangement defines a molecular subset of NSCLC with distinct clinical characteristics that are similar to those observed in patients with ALK-rearranged NSCLCs, and crizotinib shows in vitro activity and early evidence of clinical activity in ROS1- rearrangedNSCLC.